Patient has failed ≥ 14 days of Sorafenib treatment

Cirrhotic status of Child-Pugh Class A or B with a score of 7

Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, 2

Subjects who have a life expectancy of at least 8 weeks

Adequate hematologic, hepatic, and renal function

women of childbearing potential (WOCBP) who are unwilling or unable to use an acceptable method to avoid pregnancy

Previous or concurrent cancer that is distinct in primary site

History of active cardiac disease

Thrombotic or embolic events within the past 6 months

Any other hemorrhage/bleeding event \> Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 within 4 weeks

Inability to swallow tablets or untreated malabsorption syndrome

History of human immunodeficiency virus (HIV) infection

Prior use of systemic investigational agents for HCC (except for Sorafenib)

Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment